Back to Browse Journals » Vascular Health and Risk Management » Volume 5

Update on the everolimus-eluting coronary stent system: results and implications from the SPIRIT clinical trial program

Authors

R Michael Kirchner, J Dawn Abbott

Published 16 December 2009 Volume 2009:5 Pages 1089—1097

DOI https://doi.org/10.2147/VHRM.S5618

Review by Single-blind

Peer reviewer comments 2

R Michael Kirchner, J Dawn Abbott

Department of Cardiology, Rhode Island Hospital, Brown Medical School, Providence, RI, USA

Abstract: Drug-eluting stents (DES) have had a major impact in interventional cardiology. Compared to bare metal stents, they significantly reduce restenosis and the need for target vessel revascularization. Four DES are available in the US, the first-generation sirolimuseluting (Cypher®) and paclitaxel-eluting (Taxus®) stents and later approved second-generation everolimus-eluting (Xience V®) and zotarolimus-eluting (Endeavor®) stents. The Xience V stent was approved on the basis of clinical efficacy and safety data from 3 studies in the SPIRIT clinical trial program. Within this trial series, the Xience V was superior to its bare metal stent counterpart, the Vision® stent, and noninferior to the paclitaxel-eluting stent for target vessel failure at 9 months. This review provides a comprehensive assessment of the data derived from both the pre- and post-approval randomized controlled trials and registry studies of Xience V that comprise the SPIRIT clinical trial program including recently published mid-term outcomes. The implications of the results in terms of interventional practice will be discussed.

Keywords: cobalt-chromium, drug-eluting stent, everolimus, percutaneous coronary intervention, Xience V

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Tivozanib in the treatment of renal cell carcinoma

Hepgur M, Sadeghi S, Dorff TB, Quinn DI

Biologics: Targets and Therapy 2013, 7:139-148

Published Date: 11 June 2013

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

Nooka A, Gleason C, Casbourne D, Lonial S

Biologics: Targets and Therapy 2013, 7:13-32

Published Date: 30 January 2013

Erratum - Intracellular heavy metal nanoparticle storage

Iannitti T, Capone S, Gatti A, et al

International Journal of Nanomedicine 2011, 6:239-240

Published Date: 26 January 2011